Tacrolimus decreases insulin sensitivity without reducing fasting insulin concentration: a 2-year follow-up study in

Qing-Jie Chen1, Jing Li, Shan-Ru Zuo

  • 1Clinical Pharmacy and Pharmacology Research Institute, The Third Xiangya Hospital of Central South University , Changsha, Hunan , PR China .

Renal Failure
|February 4, 2015
PubMed

Insights

New Onset Diabetes after Transplantation (NODAT) is primarily caused by insulin resistance, not specific gene variations in IRS-1 or IRS-2. Tacrolimus treatment in kidney transplant patients showed elevated insulin levels in NODAT patients, indicating resistance as the main driver.

Area of Science:

  • Nephrology
  • Endocrinology
  • Immunology

Background:

  • New Onset Diabetes after Transplantation (NODAT) is a significant complication in transplant recipients.
  • Tacrolimus, a common immunosuppressant, is associated with increased NODAT risk.
  • Understanding the mechanisms behind NODAT is crucial for patient management.

Purpose of the Study:

  • To investigate the impact of tacrolimus on insulin secretion and sensitivity in kidney transplant recipients.
  • To determine the association between NODAT and single-nucleotide polymorphisms (SNPs) in IRS-1 and IRS-2 genes.
  • To identify the primary cause of tacrolimus-induced NODAT.

Main Methods:

  • A cohort study involving 158 kidney transplant patients treated with tacrolimus.
  • Division of patients into NODAT and non-NODAT groups.
  • Measurement of plasma fasting insulin and C-peptide levels.
  • Genotyping of IRS-2 Gly1057Asp and IRS-1 Gly972Arg polymorphisms using PCR fragment length polymorphism.

Main Results:

  • Patients with NODAT and non-NODAT groups treated with tacrolimus exhibited higher fasting insulin and C-peptide levels than healthy volunteers.
  • Fasting plasma insulin levels were significantly higher in the NODAT group compared to the non-NODAT group.
  • No significant differences were observed in C-peptide levels or in the allele/genotype frequencies of IRS-2 Gly1057Asp and IRS-1 Gly972Arg between NODAT and non-NODAT patients.

Conclusions:

  • Insulin resistance is the principal factor contributing to tacrolimus-induced NODAT.
  • The studied genetic variations in IRS-2 and IRS-1 do not appear to be associated with the development of NODAT in this cohort.

Related Concept Videos

Kidney Transplant II: Surgical Procedure01:26

Kidney Transplant II: Surgical Procedure

Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
872
Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
782
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
994
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.3K
Kidney Transplant III: Nursing Management01:16

Kidney Transplant III: Nursing Management

Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...
603